Clinical trial NCT01422707: Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Official title: Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: EARLY_PHASE1
Conditions: Hyperandrogenemia
Obesity
Polycystic Ovary Syndrome
Lead sponsor: University of Virginia
Sponsor class: OTHER
First posted: 2011-08-24
Enrollment: 0
Sex: FEMALE
Minimum age (years): 7
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Short term hydrocortisone to test whether improves excess androgen production from adrenal gland and ovaries

Detailed description: This study will test whether short-term suppression of adrenal function can ameliorate androgen (male hormone) overproduction in overweight girls with androgen excess. The investigators hypothesize that one month of oral hydrocortisone administration will improve androgen levels in girls with adrenal androgen overproduction. Specifically, this intervention will improve androgen levels after adrenal stimulation testing with adrenocorticotropin hormone (ACTH).

Eligibility criteria: Inclusion Criteria:

* Overweight(\>85th BMI%) females
* Early to late puberty (expected age range 7-18)
* Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage)
* Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could include mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)

Exclusion Criteria:

* Screening labs outside of age-appropriate normal range
* Hemoglobin \<12 mg/dL and hematocrit\<36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit. If still \<36%, they will be excluded.)
* Morning Cortisol \<5 g/dL
* 17-hydroxyprogesterone \>295 ng/dL
* History of Cushing's syndrome or adrenal insufficiency
* Pregnant

Primary outcomes:
measure: Changes in free testosterone after ACTH administration before and after hydrocortisone administration for 4 weeks
timeFrame: 30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration
Secondary outcomes:
measure: Changes in adrenal steroid precursors after ACTH, baseline, and after 4 weeks of hydrocortisone administration
timeFrame: 30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia Center for Research in Reproduction
state: Virginia
Study officials:
affiliation: University of Virginia
name: Christine M. Burt Solorzano, MD
role: PRINCIPAL_INVESTIGATOR
References: